Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York. more
Time Frame | INDP | Sector | S&P500 |
---|---|---|---|
1-Week Return | -6.98% | -2.06% | -0.55% |
1-Month Return | -17.13% | -1.92% | 2.72% |
3-Month Return | -35.35% | -10.4% | 7.66% |
6-Month Return | -63.39% | -4.6% | 10.15% |
1-Year Return | -51.25% | 4.06% | 27.53% |
3-Year Return | -83.75% | 1.94% | 32.31% |
5-Year Return | -97.63% | 36.48% | 89.2% |
10-Year Return | -99.81% | 97.46% | 194.59% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | 854.00K | 852.00 | 1.40K | 1.78K | 1.28K | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":0.1,"profit":true},{"date":"2021-12-31","value":0.16,"profit":true},{"date":"2022-12-31","value":0.21,"profit":true},{"date":"2023-12-31","value":0.15,"profit":true}] |
Gross Profit | (854.00K) | (852.00) | (1.40K) | (1.78K) | (1.28K) | [{"date":"2019-12-31","value":-85400000,"profit":false},{"date":"2020-12-31","value":-85200,"profit":false},{"date":"2021-12-31","value":-140300,"profit":false},{"date":"2022-12-31","value":-178100,"profit":false},{"date":"2023-12-31","value":-128400,"profit":false}] |
Gross Margin | - | (Infinity%) | (Infinity%) | (Infinity%) | (Infinity%) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":null,"profit":false}] |
Operating Expenses | 34.09M | 3.60M | 7.73M | 14.91M | 16.38M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":10.56,"profit":true},{"date":"2021-12-31","value":22.67,"profit":true},{"date":"2022-12-31","value":43.74,"profit":true},{"date":"2023-12-31","value":48.04,"profit":true}] |
Operating Income | (34.95M) | (3.60M) | (7.73M) | (14.91M) | (16.38M) | [{"date":"2019-12-31","value":-3494600000,"profit":false},{"date":"2020-12-31","value":-359926500,"profit":false},{"date":"2021-12-31","value":-772910800,"profit":false},{"date":"2022-12-31","value":-1491090600,"profit":false},{"date":"2023-12-31","value":-1637847400,"profit":false}] |
Total Non-Operating Income/Expense | - | 30.23K | 35.44K | 1.18M | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":2.57,"profit":true},{"date":"2021-12-31","value":3.01,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Pre-Tax Income | (46.96M) | (3.58M) | (7.71M) | (14.32M) | (15.42M) | [{"date":"2019-12-31","value":-4696100000,"profit":false},{"date":"2020-12-31","value":-358415100,"profit":false},{"date":"2021-12-31","value":-771138600,"profit":false},{"date":"2022-12-31","value":-1432279800,"profit":false},{"date":"2023-12-31","value":-1542347100,"profit":false}] |
Income Taxes | 638.00K | (15.11K) | (17.72K) | (588.11K) | (16.38M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-2.37,"profit":false},{"date":"2021-12-31","value":-2.78,"profit":false},{"date":"2022-12-31","value":-92.18,"profit":false},{"date":"2023-12-31","value":-2567.36,"profit":false}] |
Income After Taxes | - | (3.57M) | (7.69M) | (13.73M) | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-356903700,"profit":false},{"date":"2021-12-31","value":-769366400,"profit":false},{"date":"2022-12-31","value":-1373469000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income From Continuous Operations | - | (3.58M) | (7.71M) | (14.32M) | (15.08M) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-358415100,"profit":false},{"date":"2021-12-31","value":-771138600,"profit":false},{"date":"2022-12-31","value":-1432279800,"profit":false},{"date":"2023-12-31","value":-1507646800,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (47.60M) | (3.57M) | (7.69M) | (13.73M) | (15.42M) | [{"date":"2019-12-31","value":-4759900000,"profit":false},{"date":"2020-12-31","value":-356903700,"profit":false},{"date":"2021-12-31","value":-769366400,"profit":false},{"date":"2022-12-31","value":-1373469000,"profit":false},{"date":"2023-12-31","value":-1542347100,"profit":false}] |
EPS (Diluted) | (89.60) | (16.32) | (10.40) | (1.73) | (1.85) | [{"date":"2019-12-31","value":-8960,"profit":false},{"date":"2020-12-31","value":-1632,"profit":false},{"date":"2021-12-31","value":-1040,"profit":false},{"date":"2022-12-31","value":-173,"profit":false},{"date":"2023-12-31","value":-185,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
INDP | |
---|---|
Cash Ratio | 3.31 |
Current Ratio | 3.42 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
INDP | |
---|---|
ROA (LTM) | -71.12% |
ROE (LTM) | -127.04% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
INDP | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.27 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.73 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
INDP | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 1.82 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | 1.03 |
Indaptus Therapeutics Inc (INDP) share price today is $0.9116
Yes, Indians can buy shares of Indaptus Therapeutics Inc (INDP) on Vested. To buy Indaptus Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in INDP stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Indaptus Therapeutics Inc (INDP) via the Vested app. You can start investing in Indaptus Therapeutics Inc (INDP) with a minimum investment of $1.
You can invest in shares of Indaptus Therapeutics Inc (INDP) via Vested in three simple steps:
The 52-week high price of Indaptus Therapeutics Inc (INDP) is $3.1. The 52-week low price of Indaptus Therapeutics Inc (INDP) is $0.84.
The price-to-earnings (P/E) ratio of Indaptus Therapeutics Inc (INDP) is
The price-to-book (P/B) ratio of Indaptus Therapeutics Inc (INDP) is 1.82
The dividend yield of Indaptus Therapeutics Inc (INDP) is 0.00%
The market capitalization of Indaptus Therapeutics Inc (INDP) is $10.92M
The stock symbol (or ticker) of Indaptus Therapeutics Inc is INDP